Two phase II studies assessing the efficacy and safety of ceritinib in patients with ALK rearranged NSCLC and baseline brain metastases were presented at ESMO Asia 2015 Congress in Singapore. The second generation ALK inhibitor showed a promising clinical activity both in ASCEND-2 and ASCEND-3. Commenting the top results, S Thongprasert states that ceritinib could be an effective strategy to control brain metastases in ALK-naive and patients previously treated with crizotinib.

Oncology Meeting Resources

Major Sponsors

AstraZeneca Janssen

Main Sponsors

Amgen Bayer Healthcare Boehringer Ingelheim Daiichi Sankyo Genomic Health Inc. Lilly Oncology Roche